The Exopharm (ASX:EX1) share price is sliding today after the company’s osteoarthritis animal treatments showed no effect on the rats studied.
The post Exopharm (ASX:EX1) share price plunges 17% after animal testing results appeared first on The Motley Fool Australia. –
The Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinical data from its osteoarthritis animal study, showing its two regenerative medical products had no effect on the rats studied.
At the time of writing, the Exopharm share price is down 15.7%, trading at 59 cents after hitting an intraday low of 55 cents.
Exopharm is a biopharmaceutical company focused on developing regenerative medicine. It’s currently investigating the therapeutic potential of two products, Plexaris and Cevaris, in treating osteoarthritis.
The company also aims to commercialise exosomes as therapeutic agents. Exosomes are membraneous structures that allow cells to communicate and have the potential to restore dying cells.
Exopharm develops its products using mainly the LEAP (linked engineering and production) process, which involves total control over each step from engineering to manufacturing.
Exopharm plunges on less-than-exciting results
In today’s release, Exopharm advised its study on rodents found 3 key results. Firstly, if a knee joint is too damaged by osteoarthritis and there isn’t enough cell tissue remaining to begin restoration, neither Plexaris nor Cevaris have any noticeable effect.
This appears to be the driving force behind the Exopharm share price decline today.
However, the company release also showed that the exosome treatments were “safe and well-tolerated following multiple (4 x weekly) dosing in rodents”.
Exopharm’s report outlined that, in conjunction with prior preclinical work, results from this study directed product development to target “mild-to-moderate stage osteoarthritis”.
What Exopharm management said
Exopharm product evaluation head, Dr Angus Tester, said the study results were largely meaningless due to the rats studied.
Initially, we were surprised to see no beneficial effect of either Plexaris or Cevaris over control until we looked at the knee scans. We realised that in this testing, the knee joints were damaged beyond repair, with no obvious cartilage cells available to respond to the exosome treatment.
To accurately evaluate the exosome efficacy, we will need to have a model that has a less severe joint damage as the baseline to gather meaningful efficacy data.
Exopharm share price snapshot
Exopharm insists that the damage it inflicted to the rats’ knee joints for the study would, in a human, require a knee reconstruction and therefore surpasses the viability of medical treatment. However, shareholders are clearly concerned that these results may limit the potential efficacy of its treatments.
The Exopharm share price has now fallen 26% this week and 24% this month, after huge gains, saw the Exopharm share price rise from 33 cents in December 2020 to 94 cents in February this year.
Overall, the Exopharm share price is up 271% this past year.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why the Acrow (ASX:ACF) share price is running higher today
- Universal Biosensors (ASX:UBI) share price is lifting today. Here’s why
- Why the Xero (ASX:XRO) share price outperformed in March
- Creso (ASX:CPH) share price edges higher on product launch
- Here’s why ASX cannabis shares are lighting up today
Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.